Ruth Asch
Associate Research Scientist in PsychiatryCards
Appointments
Psychiatry
Primary
Contact Info
Yale School of Medicine
40 Temple Street, Suite 7C, Office 750
New Haven, CT 06519
United States
About
Titles
Associate Research Scientist in Psychiatry
Appointments
Psychiatry
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- PhD
- University of Cincinnati, Neuroscience (2020)
- BA
- Mount Holyoke College, Biological Sciences (2011)
- BA
- Mount Holyoke College, Psychology (2011)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Ruth Asch's published research.
Publications Timeline
A big-picture view of Ruth Asch's research output by year.
Irina Esterlis, PhD
Richard Carson, PhD
Ansel Hillmer, PhD
Nicole DellaGioia
Hilary Blumberg, MD
Maggie Taylor Davis, PhD
25Publications
160Citations
Publications
2024
Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression
Asch R, Abdallah C, Carson R, Esterlis I. Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression. Neuropsychopharmacology 2024, 1-11. PMID: 39039139, DOI: 10.1038/s41386-024-01913-3.Peer-Reviewed Original ResearchAltmetricConceptsStudies of depressionAnimal models of chronic stressPositron emission tomographyModel of chronic stressSV2A imagingSynaptic densitySignificant depressive symptomsDevelopment of novel radiotracersDepressive symptomsNeuropsychiatric disordersSymptom severityChronic stressDrug challengeSynaptic vesicle glycoprotein 2 ANeural markersAnimal modelsSynaptic alterationsSynaptogenesis in vivoPreliminary findingsIn vivo quantificationCentral nervous systemDepressionEmission tomographySV2ASV2A positron emission tomographyW35 Nicotine Use and Metabotropic Glutamate Receptor 5 (mGluR5) in Individuals With Major Depressive and Post Traumatic Stress Disorders
Baldassarri S, Asch R, Hillmer A, Pietrzak R, DellaGioia N, Esterlis I, Davis M. W35 Nicotine Use and Metabotropic Glutamate Receptor 5 (mGluR5) in Individuals With Major Depressive and Post Traumatic Stress Disorders. Drug And Alcohol Dependence 2024, 260: 110653. DOI: 10.1016/j.drugalcdep.2023.110653.Peer-Reviewed Original ResearchDeficits in prefrontal metabotropic glutamate receptor 5 are associated with functional alterations during emotional processing in bipolar disorder
Asch R, Worhunsky P, Davis M, Holmes S, Cool R, Boster S, Carson R, Blumberg H, Esterlis I. Deficits in prefrontal metabotropic glutamate receptor 5 are associated with functional alterations during emotional processing in bipolar disorder. Journal Of Affective Disorders 2024, 361: 415-424. PMID: 38876317, PMCID: PMC11250898, DOI: 10.1016/j.jad.2024.06.025.Peer-Reviewed Original ResearchConceptsMetabotropic glutamate receptor 5Bipolar disorderGlutamate receptor 5Positron emission tomographyFear processingEmotional processingAssociated with greater activationEmotion processing taskAssociated with impulsivityFunctional brain differencesAssociated with functional alterationsParietal brain regionsPathology of BDIncreased cortical activityAssociated with difficultiesDepressive disorderHealthy comparisonReceptor availabilityBrain differencesPre/postcentral gyriAttention difficultiesGreater activationBrain regionsPsychomotor functionTreatment developmentFirst-in-Human Study of 18F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding
Drake L, Wu Y, Naganawa M, Asch R, Zheng C, Najafzadeh S, Pracitto R, Lindemann M, Li S, Ropchan J, Labaree D, Emery P, Dias M, Henry S, Nabulsi N, Matuskey D, Hillmer A, Gallezot J, Carson R, Cai Z, Huang Y. First-in-Human Study of 18F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding. Journal Of Nuclear Medicine 2024, 65: jnumed.123.266470. PMID: 38360052, PMCID: PMC10924160, DOI: 10.2967/jnumed.123.266470.Peer-Reviewed Original ResearchCitationsAltmetricConceptsFirst-in-human studyPlasma free fractionTime-activity curvesCentrum semiovaleNonhuman primate's resultsFirst-in-humanFree fractionNondisplaceable binding potentialRegional time-activity curvesLow nonspecific uptakeRegional distribution volumesHigh-resolution research tomograph scannerTest-retest reproducibilityCerebral blood flowSynaptic vesicle glycoprotein 2AHealthy volunteersArterial input functionNonspecific uptakePET imaging probeDistribution volumeSynapse densityIndividual MR imagesHighest specific bindingMR imagingPET imagingPreliminary Study of White Matter Abnormalities and Associations With the Metabotropic Glutamate Receptor 5 to Distinguish Bipolar and Major Depressive Disorders
Fan S, Asch R, Davis M, DellaGioia N, Cool R, Blumberg H, Esterlis I. Preliminary Study of White Matter Abnormalities and Associations With the Metabotropic Glutamate Receptor 5 to Distinguish Bipolar and Major Depressive Disorders. Chronic Stress 2024, 8: 24705470231225320. PMID: 38250007, PMCID: PMC10798116, DOI: 10.1177/24705470231225320.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMetabotropic glutamate receptor 5Bipolar disorderGlutamate receptor 5UF FAUncinate fasciculusFractional anisotropyWhole-brain analysisMultimodal neuroimaging approachDifferentiation of BDDiffusion-weighted MRI scansFrontotemporal dysconnectivityFrontotemporal systemFunctional dysconnectivityDepressive disorderNeurobiological mechanismsMGluR5 levelsWhite matterWhite matter abnormalitiesNeuroimaging approachesWM integrityNeural mechanismsMDDWhole-brainWM abnormalitiesReceptor 5
2023
Evaluating infusion methods and simplified quantification of synaptic density in vivo with [11C]UCB-J and [18F]SynVesT-1 PET
Asch R, Naganawa M, Nabulsi N, Huan Y, Esterlis I, Carson R. Evaluating infusion methods and simplified quantification of synaptic density in vivo with [11C]UCB-J and [18F]SynVesT-1 PET. Cerebrovascular And Brain Metabolism Reviews 2023, 43: 2120-2129. PMID: 37669455, PMCID: PMC10925870, DOI: 10.1177/0271678x231200423.Peer-Reviewed Original ResearchCitationsNicotine Use and Metabotropic Glutamate Receptor 5 in Individuals With Major Depressive and Posttraumatic Stress Disorders
Baldassarri S, Asch R, Hillmer A, Pietrzak R, DellaGioia N, Esterlis I, Davis M. Nicotine Use and Metabotropic Glutamate Receptor 5 in Individuals With Major Depressive and Posttraumatic Stress Disorders. Chronic Stress 2023, 7: 24705470231154842. PMID: 36843572, PMCID: PMC9943964, DOI: 10.1177/24705470231154842.Peer-Reviewed Original ResearchCitationsAltmetricExamining mGlu5 Receptor Availability as a Predictor of Vulnerability to PTSD: An [18F]FPEB and PET Study in Male and Female Rats
Asch R, Fowles K, Pietrzak R, Taylor J, Esterlis I. Examining mGlu5 Receptor Availability as a Predictor of Vulnerability to PTSD: An [18F]FPEB and PET Study in Male and Female Rats. Chronic Stress 2023, 7: 24705470231215001. PMID: 38024327, PMCID: PMC10666551, DOI: 10.1177/24705470231215001.Peer-Reviewed Original ResearchCitationsConceptsPost-traumatic stress disorderReceptor availabilityFemale ratsPathophysiology of PTSDFootshock exposureMetabotropic glutamate receptor 5Recent preclinical findingsGlutamate receptor 5Positron emission tomographyPreclinical findingsClinical findingsFe ratsReceptor 5Lower baselineEmission tomographyGreater riskPET studiesRatsStress disorderDifferential involvementPassive copingSex differencesMalesPTSD susceptibilityBaseline
2022
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
Asch R, Hillmer A, Baldassarri S, Esterlis I. The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders. International Review Of Neurobiology 2022, 168: 265-310. PMID: 36868631, DOI: 10.1016/bs.irn.2022.10.007.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsPsychiatric disordersMetabotropic glutamate receptor 5Positron emission tomography studyGlutamate receptor 5Utility of PETEmission tomography studiesPromising therapeutic targetStress-related disordersNumerous psychiatric disordersTreatment trialsGlutamate neurotransmissionGlutamate systemMGlu5 expressionSubtype 5Treatment responseMood disordersRole of mGlu5Receptor 5Therapeutic targetPsychiatric conditionsMGlu5Tomography studySubstance useTrauma disordersDisordersDifferences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder
Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder. Biological Psychiatry 2022, 93: 1099-1107. PMID: 36764853, PMCID: PMC10164841, DOI: 10.1016/j.biopsych.2022.10.018.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMajor depressive disorderMetabotropic glutamate receptor 5Glutamate receptor 5MGluR5 availabilityBipolar disorderPositron emission tomographyHC groupDepressive disorderReceptor 5Emission tomographyHealthy control individualsPossible treatment targetsGlutamate transmissionBD depressionTreatment strategiesBD groupMGluR5Depressive symptomsNovel treatmentsCognitive alterationsTreatment targetsSynaptic plasticityControl individualsAccurate diagnosisSignificant negative correlation
Links & Media
News
- February 07, 2024
Asch Selected to Receive SOBP Travel Fellowship Award
- September 07, 2023
Asch Chosen to Receive YCCI Scholar Award
- November 15, 2022Source: Biological Psychiatry
Yale Study Seeks to Understand Neurobiology Underlying Bipolar Disorder Vs. Major Depressive Disorder
- February 16, 2022
Discoveries & Impact (February 2022)
Get In Touch
Contacts
Email
Mailing Address
Yale School of Medicine
40 Temple Street, Suite 7C, Office 750
New Haven, CT 06519
United States